Is it finally time to consider the old adage that "nothing lasts forever" for the bull market as we enter 2018? Here are 10 things that could wreck the current bull market…
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
AbbVie reported better-than-expected third-quarter before the markets opened on Friday due to strong sales of Humira and Imbruvica.
Chris Lange The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for…
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull…
While it seems everything is fully priced, the good news for investors is that there is still a plethora of stocks that are cheaper than the overall S&P 500.
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
